Non-alcoholic Fatty Liver Disease

01/01/2011 - "The best treatment of AFLD/ASH is to stop drinking, and the most effective first-line therapeutic option for NAFLD/NASH is non-pharmacologic lifestyle interventions through a multidisciplinary approach including weight loss, dietary changes, physical exercise, and cognitive-behavior therapy."
05/01/2012 - "Weight loss of 2.7±5.0kg was significantly associated with NAFLD remission. "
07/01/2008 - "Lifestyle intervention with diet and increased physical activity induces weight loss and is associated with a significant improvement in liver histology and laboratory abnormalities in pediatric NAFLD. "
03/01/2008 - "Weight loss appears to improve NAFLD, and dietary advice and lipid-lowering drugs may be beneficial for patients with NAFLD and dyslipidaemia even if weight loss is not achieved. "
09/01/2013 - "While 97% of patients with weight loss of more than 10% had remission of NAFLD, 41% of those with weight loss of 3.0-4.9% could also achieve the primary outcome. "

07/21/2014 - "Notably, GLP-1-based therapies are reported to be effective in improving hepatic endpoints in patients with NAFLD, such as reducing hepatic fat content, hepatic steatosis and plasma transaminase levels, and preventing fibrosis. "
10/01/2013 - "However, the efficacy of peripherally-restricted CB1 antagonists with limited brain penetrance has now been validated in preclinical models of NAFLD, and beneficial effects on fibrosis and its complications are anticipated. "
06/01/2013 - "Besides, NAFLD fibrosis score underlined a significant reduction (p < 0.04) in the ALAUDCA group, while AST/ALT ratio presented a moderate decline (p > 0.05). "
03/01/2011 - "These modalities and algorithms have improved significantly in their diagnosis and staging of fibrosis and NASH in patients with NAFLD, and will likely impact on the number of patients undergoing liver biopsy. "
10/01/2015 - "Our preliminary findings indicate that FibroMeter VCTE is superior to both NFSA and TE for the diagnosis of severe fibrosis in patients with NAFLD."

07/01/2011 - "Improvement in insulin resistance is the clinical parameter most strongly associated with improvement in NAFLD. "
01/01/2015 - "In human studies, FXR agonists improve insulin resistance and have recently been shown to improve NAFLD. "
08/01/2015 - "Adenoviral overexpression of STAMP2 improved insulin resistance in the HFD-induced NAFLD mice. "
01/01/2015 - "CTS from I. latifolia improved insulin resistance and liver injury in HFD-fed mice, and attenuated NAFLD via the activation of AMPK and inhibition of the gene expression of SREBPs and some of their target molecules."
07/27/2012 - "Life style modification improves insulin resistance resulting in improvement in ALT and liver histology in NAFLD patients."

01/01/2012 - "For some patients with NAFLD/nonalcoholic steatohepatitis, pharmacological treatment is the best option, although further studies are needed to confirm its efficacy and tolerability."
01/01/2006 - "No therapy has been proven effective for treating NAFLD/nonalcoholic steatohepatitis. "
09/01/2015 - "The NAFLD group was categorized into an improved group (n = 110) and a sustained NAFLD group (n = 618) based on fatty liver disappearance at the second visit. "
01/01/2013 - "While risk factors for steatohepatitis have been identified, little work has been performed to identify factors protective against NAFLD development. "
08/01/2015 - "The potential efficacy of liver selective NO donors against liver steatosis and novel treatment approaches to modulate LSECs-driven liver pathology including NAFLD are also highlighted. "

01/01/2015 - "Dietary supplementation with CoQ has been found to be hepatoprotective and to reduce oxidative stress and inflammation as well as improving mitochondrial dysfunction, suggesting that it may be beneficial in NAFLD. "
08/01/2011 - "Although the molecular mechanisms of probiotics have not been completely elucidated yet, many of their effects have proved to be beneficial in NAFLD, including the modulation of the intestinal microbiota, an antibacterial substance production, an improved epithelial barrier function and a reduced intestinal inflammation. "
07/01/2008 - "A significant improvement occurred in the grade of steatosis, lobular inflammation, and hepatocyte ballooning, and in the NAFLD activity score in both groups. "
03/01/2012 - "Fish oil improves lipid metabolism and ameliorates inflammation in patients with metabolic syndrome: impact of nonalcoholic fatty liver disease."
08/01/2015 - "The present study seeks to develop a simple mouse model of NAFLD-enhanced skin inflammation and to study the effect of NAFLD on different parameters of skin inflammation. "